Asthma in the real world

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 70-71

  O'Byrne, Paul M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adherence; Inhaled corticosteroids; Leukotriene receptor antagonists; Long acting inhaled agonists

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADD ON THERAPY; ASTHMA; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG EFFICACY; EDITORIAL; HOSPITALIZATION; HUMAN; INHALER; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84882810543     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.03.052     Document Type: Editorial

References (13)

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
2. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008;31: 320-5.
3. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
4. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21:66-74.
5. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010;125:600-8.
6. Bousquet J, Mantzouranis E, Cruz AA, it-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38.
7. Rand CS. Non-adherence with asthma therapy: more than just forgetting. J Pediatr 2005;146:157-9.
8. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-707.
9. Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled corticoste-roids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2002;(3):CD002314.
10. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011;13:217-24.
11. Sadatsafavi M, Lynd LD, Marra CA, Bedouch P, FitzGerald JM. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthma: a population based study. J Allergy Clin Immunol 2013;132: 63-9.
12. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;(4):CD003137.
13. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009;360:1671-2.